Medexus Pharmaceuticals Inc. (TSE:MDP) Given Consensus Rating of “Buy” by Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have earned an average rating of “Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and four have issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is C$5.49.

MDP has been the topic of a number of analyst reports. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a research report on Wednesday, January 8th. Stifel Canada cut Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Ventum Financial raised their price target on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Finally, Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the stock from C$6.00 to C$3.45 in a research report on Friday, February 7th.

Medexus Pharmaceuticals Stock Down 1.8 %

Shares of Medexus Pharmaceuticals stock opened at C$2.71 on Thursday. The stock has a market cap of C$60.67 million, a price-to-earnings ratio of 12.96 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.50 and a twelve month high of C$5.56. The company’s fifty day moving average is C$2.51 and its 200 day moving average is C$2.89.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.